CRNX
Crinetics Pharmaceuticals Inc
85.00$
+0.0%
vs. previous close
Closing price · As of: Sep 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -92.4% | +1,748.9% | -23.1% | -17.5% | -16.3% | +48.6% | -16.6% | +42.5% | -53.0% | -100.0% | – | -36.4% | -77.9% | -100.0% | – | – | – | – | +11.2% | +17,211.7% | +190.4% | -86.0% | +4.3% | +54.8% | +277.9% | -63.1% | -65.0% | -100.0% | – | -37.7% | -100.0% | – | – | +185.6% | -86.1% | +4,208.4% | +74.2% | +134.0% | – | |
| – | -68.4% | +0.9% | +21.1% | +1.5% | +84.2% | +10.6% | +31.9% | +11.1% | -5.2% | +41.8% | +15.0% | +2.7% | +14.2% | -9.1% | +8.7% | +22.9% | +4.5% | +16.5% | +5.3% | +14.0% | +14.8% | +16.8% | -3.1% | +15.6% | +4.0% | +5.6% | +7.9% | +4.0% | -99.0% | +58.9% | +8,121.1% | +7.5% | -100.0% | – | +9,333.2% | -100.5% | – | -23.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +190.4% | -86.0% | +4.3% | +54.8% | +277.9% | -63.1% | -65.0% | -13,273.4% | – | -37.7% | -15,615.0% | – | – | +185.6% | -86.1% | +4,208.4% | +71.0% | +137.0% | – | |
| – | -59.5% | +0.9% | +21.1% | +1.5% | +84.2% | +10.6% | +31.9% | +11.1% | -5.2% | +41.8% | +15.0% | +2.7% | +14.2% | -9.1% | +8.7% | +22.9% | +4.8% | +17.3% | +4.8% | +13.5% | +14.8% | +16.8% | -3.1% | +15.6% | +4.0% | +5.6% | +7.9% | +4.1% | +16.9% | +9.4% | +6.1% | +7.5% | +14.5% | +5.3% | +12.7% | -6.0% | +17.7% | -0.2% | – | |
| – | -61.6% | -33.4% | +25.3% | -4.9% | +167.2% | -10.4% | +54.9% | +47.9% | +23.2% | -3.0% | +27.8% | -13.3% | +17.7% | +8.3% | +9.9% | +4.4% | +7.5% | +5.0% | +11.2% | +18.2% | +18.3% | +20.5% | +13.7% | -5.5% | +8.1% | +9.5% | +16.0% | +10.3% | +22.0% | +19.3% | +4.2% | +8.8% | +26.1% | +40.3% | +4.9% | +2.7% | -5.3% | +13.3% | – | |
| – | -60.7% | -37.0% | +44.5% | +5.3% | +121.0% | +2.8% | +42.0% | +16.9% | +6.5% | +32.9% | +14.1% | -0.1% | +16.9% | -4.8% | +9.0% | +18.1% | -75.5% | +5.0% | +11.2% | +413.3% | +15.6% | +17.7% | +1.0% | +9.9% | +5.0% | +6.6% | +9.9% | -71.2% | +334.3% | +12.2% | -68.9% | +8.8% | +296.6% | +16.4% | +9.7% | -2.0% | +7.9% | +4.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -81.8% | +50.0% | -33.3% | -50.0% | -100.0% | – | – | – | – | – | – | – | – | -53.2% | -53.1% | -56.6% | -43.4% | -23.3% | +4.3% | +448,347.3% | -99.8% | +273.1% | +108.3% | +26.9% | +4.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -183.8% | – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.